34 results
424B3
QTTB
Q32 Bio Inc.
29 Apr 24
Prospectus supplement
5:10pm
recruitment or the ability of enrolled subjects to complete our clinical trials or could result in potential product liability claims. Potential side
8-K
EX-99.2
QTTB
Q32 Bio Inc.
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm
tolerability versus other therapies. Treatment-emergent adverse events could also affect patient recruitment or the ability of enrolled subjects
424B3
QTTB
Q32 Bio Inc.
13 Mar 24
Prospectus supplement
1:36pm
or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete … ;
developments or disputes concerning patent applications, issued patents or other proprietary rights;
the recruitment or departure of key personnel
424B3
i5pt6
14 Feb 24
Prospectus supplement
4:10pm
S-4/A
u2jp40mm
29 Jan 24
Registration of securities issued in business combination transactions (amended)
12:00am
S-4
dsy8i9c54z7tr mc4pk
15 Dec 23
Registration of securities issued in business combination transactions
7:15pm
S-4
EX-10.37
lt6z2tm9oz
15 Dec 23
Registration of securities issued in business combination transactions
7:15pm